Deutsche Bank AG Purchases Shares of 3,439,976 Geron Corporation $GERN

Deutsche Bank AG acquired a new position in shares of Geron Corporation (NASDAQ:GERN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,439,976 shares of the biopharmaceutical company’s stock, valued at approximately $4,403,000.

Several other hedge funds also recently modified their holdings of the stock. OneDigital Investment Advisors LLC acquired a new position in shares of Geron during the 2nd quarter valued at $38,000. Bank of New York Mellon Corp bought a new position in Geron in the second quarter worth approximately $2,071,000. State of Wyoming acquired a new stake in Geron in the second quarter valued at approximately $78,000. GSA Capital Partners LLP acquired a new stake in Geron in the second quarter valued at approximately $753,000. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Geron by 152.4% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,000,910 shares of the biopharmaceutical company’s stock worth $1,281,000 after purchasing an additional 604,278 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Stock Performance

NASDAQ GERN opened at $1.55 on Wednesday. Geron Corporation has a 1 year low of $1.04 and a 1 year high of $2.01. The firm has a market cap of $995.83 million, a price-to-earnings ratio of -14.09 and a beta of 0.61. The company has a fifty day moving average price of $1.43 and a 200-day moving average price of $1.48. The company has a debt-to-equity ratio of 0.55, a current ratio of 6.91 and a quick ratio of 5.16.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The firm had revenue of $57.48 million during the quarter, compared to the consensus estimate of $55.30 million. Geron had a negative return on equity of 24.48% and a negative net margin of 34.17%. As a group, equities research analysts predict that Geron Corporation will post -0.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.00.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.